文献速递神经肌肉病

遗传性神经病皮肤活检的施万细胞转录本生物标志物

Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.
PubMed 文献 · Ann Neurol · 2019-04-22

该研究开发了一种将PMP22转录本水平归一化至施万细胞特异性基因的方法,并构建定制Nanostring panel,在CMT1A患者与对照的皮肤活检中可重复地显示PMP22水平升高,尤其归一化后。该平台有望作为CMT1A临床试验中靶点 engagement 的生物标志物,用于优化剂量。

要点

  • 皮肤活检中PMP22转录本归一化至施万细胞特异性基因可区分CMT1A与对照。
  • 定制Nanostring panel实现可重复的转录本测量,校正施万细胞含量变异。
  • 该平台可作为CMT1A临床试验的靶点 engagement 生物标志物。

核心结论

  • 将PMP22转录本水平归一化至施万细胞特异性基因后,皮肤活检可区分CMT1A患者与对照。

研究设计与样本

  • 研究开发了将PMP22转录本水平归一化至施万细胞特异性基因的方法,并构建定制Nanostring panel进行转录本测量。
  • 研究在人类临床试验的皮肤活检中比较了CMT1A患者与对照的PMP22 mRNA水平。

主要发现

  • Nanostring数字表达数据显示,CMT1A患者皮肤活检中PMP22水平较对照可重复升高,尤其归一化至施万细胞特异性基因后。
  • 既往皮肤活检定量PCR测量PMP22 mRNA未显示CMT1A患者较对照升高,部分归因于皮肤中施万细胞含量变异。

临床怎么用

  • 该平台可用于CMT1A临床试验中作为靶点 engagement 的生物标志物,帮助优化剂量。
  • 相同的归一化框架可适用于其他类型的CMT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Charcot-Marie-Tooth (CMT) disease is most commonly caused by duplication of a chromosomal segment surrounding Peripheral Myelin Protein 22, or PMP22 gene, which is classified as CMT1A. Several candidate therapies reduce Pmp22 mRNA levels in CMT1A rodent models, but development of biomarkers for clinical trials in CMT1A is a challenge given its slow progression and difficulty in obtaining nerve samples. Quantitative PCR measurements of PMP22 mRNA in dermal nerves were performed using skin biopsies in human clinical trials for CMT1A, but this approach did not show increased PMP22 mRNA in CMT1A patients compared to controls. One complicating factor is the variable amounts of Schwann cells (SCs) in skin. The objective of the study was to develop a novel method for precise evaluation of PMP22 levels in skin biopsies that can discriminate CMT1A patients from controls. METHODS: We have developed methods to normalize PMP22 transcript levels to SC-specific genes that are not altered by CMT1A status. Several CMT1A-associated genes were assembled into a custom Nanostring panel to enable precise transcript measurements that can be normalized to variable SC content. RESULTS: The digital expression data from Nanostring analysis showed reproducible elevation of PMP22 levels in CMT1A versus control skin biopsies, particularly after normalization to SC-specific genes. INTERPRETATION: This platform should be useful in clinical trials for CMT1A as a biomarker of target engagement that can be used to optimize dosing, and the same normalization framework is applicable to other types of CMT. ANN NEUROL 2019;85:887-898.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Svaren J, Moran JJ, Wu X, et al. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies. Ann Neurol. 2019. PMID: 30945774. doi:10.1002/ana.25480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。